Ïã¸ÛÁùºÏ²ÊÖÐÌØÍø

XClose

Ïã¸ÛÁùºÏ²ÊÖÐÌØÍø Queen Square Institute of Neurology

Home
Menu

2024 MSA Research Symposium: Early Stages of MSA: Advancing Diagnostics, Biomarkers, & Interventions

Join us on February 9th, 2024, at the 33 Queen Square Lecture Theatre in the heart of Queen Square, to explore groundbreaking and latest MSA clinical and basic science research.

From diagnostics and biomarkers to drug trials and interventions, the MSA Research Symposium promises a day of discussions and updates, shaping the trajectory of MSA research.ÌýThis is where clinical insight meets scientific rigor and industry collaboration. Seize the opportunity to connect with pioneers like Sir John Hardy and Prof Claudio Soto, delve into alpha-synuclein genetics, navigate the intricate pathways of MSA with experts such as Prof Henry Houlden, Prof Sonia Gandhi,ÌýProf Stephen Gentleman and learn from movement disorders experts like Prof Kailash Bhatia, Prof Michele Hu, Dr Valeria Iodice, Dr Nicola Pavese and Dr Wendi Phillips.

Event organised by Dr Viorica Chelban, Ïã¸ÛÁùºÏ²ÊÖÐÌØÍø and the MSA Trust.Ìý

Agenda

9.30-10.00 Registration & Coffee

10.00-10.10 Opening remarks. Prof Sonia Gandhi, Clinical and Movement Neurosciences, Ïã¸ÛÁùºÏ²ÊÖÐÌØÍø Queen Square Institute of NeurologyÌý

10:10–11:00 New insights intoÌýalpha-synucleinÌýgenetics and biomarkers

Chair: Prof Sonia Gandhi, Clinical and Movement Neurosciences, Ïã¸ÛÁùºÏ²ÊÖÐÌØÍø Queen Square Institute of NeurologyÌý

  • Genetic analysis of synucleinopathies. Sir John Hardy. Ïã¸ÛÁùºÏ²ÊÖÐÌØÍø Queen Square Institute of NeurologyÌýÌý
  • Biochemical, biological and structural studies of alpha-synuclein aggregates in Multiple System Atrophy. ProfÌýClaudio Soto, University of Texas Medical School, USAÌýÌý

11.00-12.15 Alpha-synuclein structure, pathways, and genetic risks in MSAÌý

Chair: Prof Henry Houlden, Ïã¸ÛÁùºÏ²ÊÖÐÌØÍø Queen Square Institute of NeurologyÌý

  • Is Multiple System Atrophy a distinct strain of alpha-synucleinopathy? Prof Stephen Gentleman, Imperial College London, UKÌý
  • The role of oligodendrocytes in synucleinopathies.ÌýProf Sonia Gandhi, Clinical and Movement Neurosciences, Ïã¸ÛÁùºÏ²ÊÖÐÌØÍø Queen Square Institute of Neurology, UKÌý
  • Targeting autophagy to counteract alpha-synuclein-related pathology in MSA. Maria Xilouri, Biomedical Research Foundation of the Academy of Athens, Greece.ÌýÌý
  • Genetic risks in patients presenting with MSA. Dr Viorica Chelban. Ïã¸ÛÁùºÏ²ÊÖÐÌØÍø Queen Square Institute of Neurology.ÌýÌý

12.15-12.30 Refreshments Break

12.30-13.30ÌýMSA research: From patient to bench and back to the patientÌý

Chair: Dr Christopher Kobylecki, Manchester Centre for Clinical Neurosciences, SalfordÌý

  • Setting-up a biobank for research into neurodegenerative diseases. Amanda Helsegrave. Biomarkers lab, Ïã¸ÛÁùºÏ²ÊÖÐÌØÍø Queen Square Institute of Neurology
  • Neuroimaging tools for MSA diagnosis and progression, Nicola Pavese, Newcastle.ÌýÌý
  • ClearSpeechTogether versus standard NHS speech intervention: A single, mixed method, rater-blinded pilot randomised controlled trial for people living with MSA-C. Prof Anja Lowit, Strathclyde University Glasgow.ÌýÌý

13.30-14.30ÌýLunch Break

14.30- 15.45 Diagnosing MSA in early disease stagesÌýÌý

Chair: Prof Michele Hu, Nuffield Department of Clinical Neurosciences, University of Oxford, UKÌýÌý

  • Difficulties in diagnosis of prodromal MSA. Dr Wendi Phillips. Addenbrooke's Hospital, Cambridge, UKÌý
  • Clinical markers in early MSA disease stages. Dr Yen Goh. Ïã¸ÛÁùºÏ²ÊÖÐÌØÍø Queen Square Institute of Neurology, UK
  • MSA mimics in early stages of disease: clinical challenges and pathways to diagnosis. Prof Kailash Bhatia, Ïã¸ÛÁùºÏ²ÊÖÐÌØÍø Queen Square Institute of Neurology, UKÌý
  • The Queen Square Autonomic Prodromal (QSA-PRODROMAL) Study. Dr Valeria Iodice, Department of Brain Repair & Rehabilitation, Ïã¸ÛÁùºÏ²ÊÖÐÌØÍø Queen Square Institute of Neurology, UKÌý

15.45- 16.00 Refreshments Break

16.00-16.30 Ongoing MSA drug trials and latest updates

Chair:Ìý Prof Nick Wood, Ïã¸ÛÁùºÏ²ÊÖÐÌØÍø Queen Square Institute of Neurology, UKÌý

  • Ampreloxetine for the treatment of nOH in MSA: Clinical Trial Update.ÌýDr Valeria Iodice, Department of Brain Repair & Rehabilitation, Ïã¸ÛÁùºÏ²ÊÖÐÌØÍø Queen Square Institute of Neurology, UKÌý
  • Antisense Oligonucleotide Therapy for MSA: Horizon Trial Update. IONIS Pharmaceuticals. Katherine Meilleur, IONIS PharmaceuticalsÌý

16.45- 17.00ÌýClosing Remarks

17.00-18.30 Drinks Reception

Contact

Please contactÌýeleanor.jarvis@msatrust.org.ukÌýif you require any additional information.